2 news items
Neumora Initiates Phase 1b Trial for Alzheimer's-Related Agitation Treatment
NMRA
20 Jun 24
responses.
"We believe there is a strong rationale to evaluate the potential benefits of NMRA-511 for the treatment of agitation associated
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
NMRA
14 May 24
. "Navacaprant's novel mechanism of action has the potential for broad benefit across multiple neuropsychiatric disorders, and there is a strong
- Prev
- 1
- Next